In recent months, newly available literature and breaking discoveries have changed our understanding of treatment options, prognostic indicators, and value in various types of sarcoma. Review the latest research breakthroughs involving sarcoma targeted therapies, surgical options, disease burden, and aftercare strategies.READ MORE
Health-related quality of life and its impact on disease progression should be a consideration when selecting treatment for sarcoma.
According to a recent study, treatment with the multikinase inhibitor entrectinib produces durable responses in all of the following soft-tissue sarcomas EXCEPT...
A recent study compared the effects of laser-assisted resection with pulmonary metastasectomy in patients with extrathoracic sarcoma.
Patients with soft tissue sarcoma experienced a confirmed clinical response following treatment with a targeted therapy, according to a recent study.
Young patients with head and neck sarcoma treated with proton beam therapy had similar outcomes with less of an impact on quality of life as those treated with traditional photon radiation.
Research in Review
Tivozanib was well-tolerated and showed promising antitumor activity in patients with soft tissue sarcoma overexpressing vascular endothelial growth factors, supporting efforts for further research.
Neoadjuvant chemotherapy with epirubicin plus ifosfamide improves outcomes in patients with soft tissue sarcoma who are at high-risk of recurrence.
Results argue against the inclusion of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly responding osteosarcoma.